Highlight
Recent research demonstrates that LABD97, a proteolyzed fragment of BP180, offers superior sensitivity in ELISA serologic testing for bullous pemphigoid compared to current commercial BP180 (NC16A) and BP230 ELISAs. This antigenic target detects a higher proportion of circulating IgG autoantibodies, including in patients who test negative with existing assays, suggesting its potential to significantly improve diagnostic accuracy.
